- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01623570
Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP
Prospective Randomized Open Label Study to Compare the Efficacy and Safety of Ovarian Stimulation With Pergoveris® and Menopur® in Women With Severe Luteinizing Hormone (LH) and Follicular Stimulating Hormone (FSH) Deficiency.
The aim of the study is to compare the efficacy and safety of r-hFSH+r-hLH in a 2:1 ratio with human Menopausal Gonadotropin Highly Purified (hMG-HP), in WHO type I anovulation, HH women.
This open-label monocentric, randomized comparative trial, to receive the two different standard clinical practice treatments:
- 1 vial of Pergoveris: (vial/powder 150 International unit (IU) r-hFSH+ 75IU r-hLH)
- 2 vials of Menopur: (vials/powder hMG 75IU).
Follicular development were monitored until the protocol hCG requirement is met and a single injection of hCG was administered.
Main Outcome Measures were follicular development i.e. follicle ≥ 17 millimeters (mm), pre-ovulatory E2 ≥ 400 picomole/Liter (pmol/L) and mid-luteal phase Progesterone (P4) ≥ 25 nanomole/Liter (nmol/L).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
World Health Organization (WHO) type I hypogonadotropic anovulation (hypogonadotropic hypogonadism, HH) is a rare alteration of the reproductive system with absent or decreased function of the gonads, caused by congenital, including genetic, or acquired reduced hypothalamic or pituitary activity. This results in abnormally low serum levels of Follicular Stimulation Hormone (FSH) and Luteinizing Hormone (LH) and negligible oestrogen (E2) activity.
The most convenient treatment is daily injections of exogenous gonadotropins that has been proven to be effective.
Patients lacking an effective hypothalamic-pituitary activity (WHO type I anovulation) do not produce sufficient threshold levels of endogenous LH, which is required to obtain optimal follicular development and steroidogenesis when treated with FSH alone. Therefore a combination therapy with adequate doses of both FSH and LH in an optimal ratio is required in order to restore fertility.
The LH activity could be produced by LH itself or by human Chorionic Gonadotropin (hCG) and the two gonadotropins are available to be used in the WHO type I patients in two different formulations both in indication for this type of patients. It would be worth of interest to assess if these two different formulations could elicit the same clinical outcomes in standard clinical practice or not.
The aim of the study is to compare the efficacy and safety of recombinant human FSH and recombinant human LH (r-hFSH+r-hLH) in a 2:1 ratio with human Menopausal Gonadotropin Highly Purified (hMG-HP), containing LH-like activity, in women with severe LH and FSH deficiency (WHO type I anovulation, HH).
All patients were diagnosed with HH according to a negative progesterone (P4) challenge test, serum LH<1.2 IU/L and FSH <5 IU/L, a transvaginal ultrasound showing a uterus with a midline echo, no ovarian tumor or cyst and ≤ 13 small follicles (mean diameter ≤ 10millimeters (mm)) on the largest section through each ovary, a Body Mass Index (BMI) between 18 and 32 Kilograms for square meters(Kg/m2), and no systemic diseases.
In this open-label monocentric, randomized comparative trial, patients was randomized in two arms in 1:1 ratio, to receive the two different standard clinical practice treatments:
- 1 vial of Pergoveris: (vial/powder 150 International Units (IU) r-hFSH+ 75IU r-hLH)stimulation day 1 until required hCG level is met. The dose can be adjusted at stimulation Day 6 according to subject ovarian response and standard clinical practice
- 2 vials of Menopur: (vial/powder hMG containing 75IU FSH + 75IU LH-like activity). stimulation day 1 until required hCG level is met. The dose can be adjusted at stimulation Day 6 according to subject ovarian response and standard clinical practice Follicular development were monitored according clinical practice by ultrasound (US) and/or estradiol (E2) levels, until the protocol hCG requirement is met (i.e., at least one follicle greater than or equal to 17 mm). After this, a single injection of hCG was administered in order to induce final oocyte maturation.
Main Outcome Measures were ovulation induction as measured by follicular development i.e. follicle ≥ 17 mm, pre-ovulatory E2 ≥ 400 picomole/Liter (pmol/L) and mid-luteal phase Progesterone ≥ 25 nanomole/Liter (nmol/L). Secondary efficacy endpoints included estradiol levels/follicle at mid-cycle, number of follicles at mid-cycle and pregnancy rate (PR).
Drug safety was assessed by monitoring adverse events and the incidence of local reactions after drug injection at local site. Ovarian hyperstimulation syndrome (OHSS) was assessed and recorded according to Golan classification According to this protocol, patients were initially treated for one cycle. If consenting, patients who did not become pregnant during the first cycle were treated for a further optional one or two series of cycles with the same criteria of randomization, i.e. maintaining the same treatment as the previous cycle.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taranto, Italy, 74100
- Centro Riproduzione e Andrologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- WHO Type I HH Women
- Serum LH <1.2 IU/L
- Serum FSH <5 IU/L
- Age 25-36 years
- No ovarian tumor
- No cyst
- ≤ 13 small follicles (mean diameter ≤ 10mm)
- BMI between 18 - 32 Kg/m2
- no systemic diseases
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pergoveris: 150IU r-hFSH+ 75IU r-hLH
This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur.
Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
|
Fixed formulation of two recombinant gonadotropins
Other Names:
|
Experimental: Menopur: hMG-HP (150IU)
This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur.
Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
|
Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
E2 in pmol/L
Time Frame: Day after the protocol hCG requirement is met (at least one follicle of 17mm is monitored by ultrasound)
|
Evaluate the patients steroidogenesis
|
Day after the protocol hCG requirement is met (at least one follicle of 17mm is monitored by ultrasound)
|
Number of Follicles > 17mm
Time Frame: last US day before hCG administration
|
To evaluate the efficacy of the stimulation and maturity of follicles
|
last US day before hCG administration
|
P4 in nmol/L
Time Frame: Day after the protocol hCG requirement is met (at least one follicle of 17mm by US)
|
Progesteron level to evaluate the endometrial receptivity
|
Day after the protocol hCG requirement is met (at least one follicle of 17mm by US)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometrial thickness
Time Frame: Day 5 and Day 10 of stimulation treatment
|
Evaluation of endometrial development and receptivity
|
Day 5 and Day 10 of stimulation treatment
|
Total number of Follicles
Time Frame: Last US day before hCG administration
|
To evaluate the overall efficacy of stimulation treatment, also including follicles < 17mm
|
Last US day before hCG administration
|
Clinical Pregnancy rate
Time Frame: days 35-42 post hCG
|
Evaluate the ratio between primary end points and final stimulation outcome
|
days 35-42 post hCG
|
Occurence of any adverse events (early or late ovarian hyperstimulation syndrome)
Time Frame: Days 15-20 post hCG
|
Days 15-20 post hCG
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CREA022011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadotropic Hypogonadism
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Fudan UniversityRecruitingIdiopathic Hypogonadotropic Hypogonadism | Luteal Phase Support | Luteal Phase DeficiencyChina
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingAcquired Hypogonadotropic HypogonadismItaly
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalTerminatedHypothalamic Amenorrhea | Idiopathic Hypogonadotropic HypogonadismUnited States
-
Ferring PharmaceuticalsCompletedPrimary Amenorrhea With Hypogonadotropic HypogonadismUnited States, Canada
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Huashan HospitalRecruitingHypogonadotropic HypogonadismChina
Clinical Trials on Pergoveris: 150IU r-hFSH + 75IU r-hLH
-
Reproductive Medicine Associates of New JerseyCompletedOutcome During r-hFSH Stimulation | Outcome During r-hFSH and r-hLH StimulationUnited States
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.P.A., ItalyTerminated
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyMerck Pte. Ltd., SingaporeCompleted
-
Finox AGCompleted
-
Finox AGCompleted
-
Medical University of ViennaSuspended
-
Merck KGaA, Darmstadt, GermanyMerck, S.L., SpainTerminated
-
Merck KGaA, Darmstadt, GermanyCompletedInfertility | Ovulation InductionSpain